How many institutions held KTTA - Pasithea Therapeutics Corp. - Common Stock, par value $0.0001 in Q1 2026?

2 institutional investors reported KTTA - Pasithea Therapeutics Corp. - Common Stock, par value $0.0001 for Q1 2026. Use the holders table for investor-level position and value details.

Pasithea Therapeutics Corp. - Common Stock, par value $0.0001 (KTTA)

Q: What does CUSIP 70261F202 represent in this 13F holders report?

CUSIP 70261F202 is the security identifier for KTTA - Pasithea Therapeutics Corp. - Common Stock, par value $0.0001 used to aggregate holder disclosures.

CUSIP: 70261F202

Q1 2026 13F Holders as of 31 Mar 2026

Type / Class: Equity / Common Stock, par value $0.0001
Shares outstanding: 24,858,270
Total 13F shares: 338,559
Share change: +32,787
Total reported value: $251,143
Price per share: $0.74
Number of holders: 2
Value change: +$24,321
Number of buys: 1

Quarterly Holders Quick Answers

What is CUSIP 70261F202?
CUSIP 70261F202 identifies KTTA - Pasithea Therapeutics Corp. - Common Stock, par value $0.0001 in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Previous quarter: Q4 2025

Recent filing periods for CUSIP 70261F202:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of KTTA - Pasithea Therapeutics Corp. - Common Stock, par value $0.0001 (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
Vivo Opportunity Fund Holdings, L.P.	13D/G	—	10%	17,560,467	$12,292,327	$0	01 Dec 2025	13D/G
JANUS HENDERSON GROUP PLC	13D/G 13F	Company	10%	10,229,652	$7,160,756	$0	28 Nov 2025	13D/G 13F
ADAGE CAPITAL PARTNERS GP, L.L.C.	13F	Company	8.4%	2,100,000	$2,709,000	—	31 Dec 2025	13F
Squadron Capital Management LLC	13F 13D/G	Company · Squadron Master Fund LP	9.9% from 13D/G	2,100,000	$2,709,000	—	31 Dec 2025	13F 13D/G
Vivo Capital, LLC	13F	Company	8.4%	2,100,000	$2,709,000	—	31 Dec 2025	13F
AMERIPRISE FINANCIAL INC	13F 13D/G	Company	8.4% from 13D/G	1,930,128	$2,489,865	—	31 Dec 2025	13F 13D/G
Coastlands Capital LP	13D/G	—	10%	2,394,765	$2,059,498	$0	23 Feb 2026	13D/G
Adage Capital Management, L.P.	13D/G	—	10%	2,329,749	$2,050,179	$0	31 Dec 2025	13D/G
PD Joint Holdings, LLC Series 2016-A	3/4/5	10%+ Owner	— class O/S missing	2,608,696	$1,124,348	—	22 Oct 2022	3/4/5
CVI Investments, Inc.	13D/G	—	3.8%	899,994	$791,995	+$64,987	31 Dec 2025	13D/G
Eric Shahinian	3/4/5	Member of 10% owner group	— class O/S missing	1,788,415	$770,807	—	28 Sep 2022	3/4/5
Cable Car Capital, LP	13F	Company	2%	500,000	$645,000	—	31 Dec 2025	13F
Orca Capital AG	13D/G	—	4.9%	362,857	$613,228	-$14,002	07 May 2025	13D/G
ACUTA CAPITAL PARTNERS, LLC	13F	Company	1.8%	450,000	$580,500	—	31 Dec 2025	13F
INTRACOASTAL CAPITAL, LLC	13D/G	Mitchell P. Kopin	5%	317,863	$537,188	$0	06 May 2025	13D/G
STEMPOINT CAPITAL LP	13F	Company	1.4%	355,082	$458,056	—	31 Dec 2025	13F
Israel Maxx Abramowitz	3/4/5	Not a 10% owner	— class O/S missing	1,051,575	$453,229	—	14 Sep 2021	3/4/5
AdvisorShares Investments LLC	13F	Company	1.2%	304,721	$393,090	—	31 Dec 2025	13F
Dean Lazer	3/4/5	Not a 10% owner	— class O/S missing	902,600	$389,021	—	14 Sep 2021	3/4/5
Eric Lazer	3/4/5	Not a 10% owner	— class O/S missing	902,600	$389,021	—	14 Sep 2021	3/4/5
Persistent Asset Partners Ltd	13F	Company	1.2%	290,555	$374,816	—	31 Dec 2025	13F
Stonepine Capital Management, LLC	13F	Company	1.1%	275,062	$354,830	—	31 Dec 2025	13F
ARMISTICE CAPITAL, LLC	13D/G 13F	Company	5%	142,082	$240,119	+$14,019	31 Mar 2025	13D/G 13F
Lawrence Steinman	3/4/5 13D/G	Director	3.1% from 13D/G	442,604 mixed-class rows	$149,768	+$100,000	28 Nov 2025	3/4/5 13D/G
Dr. Yassine Bendiabdallah	3/4/5	Chief Operating Officer, Director	— class O/S missing	300,000	$129,300	—	14 Sep 2021	3/4/5
VANGUARD GROUP INC	13F	Company	0.39%	97,675	$126,000	—	31 Dec 2025	13F
David Delaney	3/4/5	Member of 10% owner group	— class O/S missing	227,521	$98,062	—	17 Oct 2022	3/4/5
JANE STREET GROUP, LLC	13F	Company	0.24%	59,372	$76,590	—	31 Dec 2025	13F
CITADEL ADVISORS LLC	13F	Company	0.23%	56,183	$72,476	—	31 Dec 2025	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.22%	54,495	$70,302	—	31 Dec 2025	13F
TWO SIGMA INVESTMENTS, LP	13F	Company	0.2%	48,773	$62,917	—	31 Dec 2025	13F
Dr. Tiago Reis Marques	3/4/5	Chief Executive Officer, Director	— mixed-class rows	566,675 mixed-class rows	$55,000	+$24,208	28 Nov 2025	3/4/5
Magnolia Private Wealth, LLC	13F	Company	— class O/S missing	33,333	$43,000	—	31 Dec 2025	13F
NORTHERN TRUST CORP	13F	Company	0.11%	28,090	$36,236	—	31 Dec 2025	13F
Simon Dumesnil	3/4/5	Director	— mixed-class rows	78,746 mixed-class rows	$26,874	+$25,000	28 Nov 2025	3/4/5
XTX Topco Ltd	13F	Company	0.08%	20,783	$26,810	—	31 Dec 2025	13F
Dr. Emer Leahy	3/4/5	Director	— mixed-class rows	76,246 mixed-class rows	$24,999	—	28 Nov 2025	3/4/5
Avi Geller	3/4/5	Member of 10% owner group	— class O/S missing	54,644	$23,552	—	19 Aug 2022	3/4/5
Daniel H. Schneiderman	3/4/5	Chief Financial Officer	— mixed-class rows	343,933 mixed-class rows	$20,000	—	28 Nov 2025	3/4/5
UBS Group AG	13F	Company	0.05%	13,263	$17,109	—	31 Dec 2025	13F
Kepos Capital LP	13F	Company	— class O/S missing	334,600	$5,000	—	31 Dec 2025	13F
Hurley Capital, LLC	13F	Company	0.01%	3,689	$4,759	—	31 Dec 2025	13F
Tower Research Capital LLC (TRC)	13F	Company	0.01%	2,947	$3,802	—	31 Dec 2025	13F
SBI Securities Co., Ltd.	13F	Company	0%	1,051	$1,356	—	31 Dec 2025	13F
TWO SIGMA SECURITIES, LLC	13F	Company	— class O/S missing	55,579	$784	—	31 Dec 2025	13F
Marex Group plc	13F	Company	— class O/S missing	25,000	$345	—	31 Dec 2025	13F
JPMORGAN CHASE & CO	13F	Company	0%	150	$194	—	31 Dec 2025	13F
BANK OF AMERICA CORP /DE/	13F	Company	0%	63	$81	—	31 Dec 2025	13F
Alfred J. Novak	3/4/5	Director	— class O/S missing	42,913	—	—	24 Oct 2025	3/4/5
Graeme Martin Currie	3/4/5	Chief Development Officer	— class O/S missing	5,938	—	—	01 Mar 2024	3/4/5

Institutional Holders of Pasithea Therapeutics Corp. - Common Stock, par value $0.0001 (KTTA) as of Q1 2026

As of 31 Mar 2026, Pasithea Therapeutics Corp. - Common Stock, par value $0.0001 (KTTA) was held by 2 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 338,559 shares. The largest 2 holders included AdvisorShares Investments LLC and SBI Securities Co., Ltd.. This page lists 2 institutional shareholders reporting positions in this security for the Q1 2026 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q1 2026 vs Q4 2025 Across Filers

Q4 2025 holders

Q1 2026 holders

Holder diff

-22

Investor	Q4 2025 Shares	Q1 2026 Shares	Share Diff	Share Chg %	Q4 2025 Value $	Q1 2026 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.